Press Release/Jan 16, 2025 — Takara Bio USA Holdings, Inc. (TBUSH) has acquired Curio Bioscience, a leader in spatial genomics, to enhance its single-cell omics portfolio. This strategic move brings together Curio’s advanced spatial biology technologies with Takara Bio’s cutting-edge NGS and single-cell genomics tools, offering groundbreaking solutions for researchers worldwide.
“With the addition of Curio Bioscience, we continue our legacy of innovation by integrating truly single-cell spatial technology to empower researchers.”
Key Highlights:
- Strategic Acquisition: Takara Bio’s purchase of Curio Bioscience combines expertise in spatial genomics with its established single-cell and NGS solutions.
- New Technologies Added:
- Trekker: First single-cell spatial technology enabling spatially resolved molecular insights.
- Seeker: Innovative tool for mapping the entire transcriptome with high sensitivity and resolution.
- Research Impact:
- Provides spatially resolved maps of cellular organization within tissues.
- Advances research in cancer biology, neuroscience, developmental biology, and immunology.
- Strengthened Portfolio: Curio’s tools integrate seamlessly with Takara Bio’s existing products, supporting transformative research in the life sciences.
- Advisory Teams: Houlihan Lokey and Cooley LLP advised Takara Bio, while Aquilo Partners, L.P., and Dorsey & Whitney LLP supported Curio Bioscience.
About Takara Bio:
Takara Bio Inc., a global leader in biotechnology, offers solutions in NGS, gene therapy, and stem cell research, committed to advancing health and quality of life through innovation.
About Curio Bioscience:
Based in Palo Alto, California, Curio Bioscience pioneers high-resolution spatial biology tools to map the transcriptome with existing sequencing workflows.
References:
- Press release source: Takara Bio Announces Acquisition of Curio Bioscience.
- Explore more at Takara Bio’s official website: Takara Bio.